GlassScriptPhysician profile
Pravinchandra Patel
NPI 1992749477
$3,377.38
in general payments reported to CMS, 2019-2025
24 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $291 · 2021: $769 · 2022: $295 · 2023: $201 · 2024: $453 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $819.04 | 2019-2024 | |
| Glaxosmithkline, LLC. | $415.62 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $381.82 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $259.10 | 2019-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $241.66 | 2019-2025 | Farxiga, Breztri |
| Astellas Pharma US INC | $235.63 | 2019-2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $115.99 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $92.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $83.84 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.34 | 2019-2025 | Xifaxan |
| Mylan Specialty L.P. | $80.28 | 2019 | |
| Exact Sciences Corporation | $70.09 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $66.71 | 2021-2022 | |
| Pfizer INC. | $66.03 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $63.62 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $37.04 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $34.33 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $31.80 | 2022-2023 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $18.38 | 2022 | |
| Gilead Sciences, INC. | $15.50 | 2020 | |
| Amgen INC. | $13.82 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.14 | 2024 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $12.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pravinchandra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.